Alcobra Ltd. Ord (ADHD) 4.31 $ADHD Alcobra Granted

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alcobra Ltd. Ord (ADHD) 4.31 $ADHD

Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
GlobeNewswire - Tue Jul 19, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the European Commission (EC) has granted Orphan Drug designation to Metadoxine for the treatment of Fragile X Syndrome within the European Union.
ADHD: 4.31 (+0.03)

Alcobra Ltd. to Participate in Upcoming Investment Conferences
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3 Annual Healthcare Day.
ADHD: 4.31 (+0.03)

Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:30AM CDT
Alcobra Ltd (ADHD) was a big mover last session, as the company saw its shares rise over 6% on the day.
ADHD: 4.31 (+0.03), JNP: 7.50 (-0.04)

The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
Zacks Equity Research - Zacks Investment Research - Mon May 16, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
SNDX: 12.22 (-0.20), EDIT: 25.70 (-0.02), ADHD: 4.31 (+0.03), MCRB: 9.73 (-1.21), NEOS: 8.84 (+0.01)

Alcobra reports 1Q loss
Automated Insights - Mon May 16, 7:15AM CDT
TEL AVIV, Israel (AP) _ Alcobra Ltd. (ADHD) on Monday reported a loss of $5.1 million in its first quarter.
ADHD: 4.31 (+0.03)

Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 16, 7:00AM CDT
-- Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 4.31 (+0.03)

Drug Stocks' Earnings to Watch on May 16: ADHD, MCRB & More
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:26AM CDT
What's in store for drug stocks, Alcobra, Seres and others when they report their first-quarter results on May 16?
SNDX: 12.22 (-0.20), EDIT: 25.70 (-0.02), ADHD: 4.31 (+0.03), MCRB: 9.73 (-1.21), NEOS: 8.84 (+0.01)

Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16
GlobeNewswire - Wed May 04, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
ADHD: 4.31 (+0.03)

MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.31 (+0.03), MEIP: 1.47 (+0.11)

Falling Earnings Estimates Signal Weakness Ahead for Valeant Pharmaceuticals (VRX)
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:53AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
VRX: 20.89 (-1.41), ADHD: 4.31 (+0.03)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.31 (+0.03), REPH: 9.70 (-0.21)

What Falling Estimates & Price Mean for Lannett (LCI)
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:40AM CDT
Lannett has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
LCI: 31.10 (-0.12), ADHD: 4.31 (+0.03)

Alcobra (ADHD) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:34AM CDT
Alcobra Ltd. (ADHD) has been struggling lately, but the selling pressure may be coming to an end soon
ADHD: 4.31 (+0.03)

Grab These 4 Incredible Momentum Stocks for Less Than $10
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 9:10AM CDT
Momentum investing grants success to those who can effectively ride the upswing and brave the downswing of the market with the same elan.
PRMW: 11.76 (-0.22), ADHD: 4.31 (+0.03), VSLR: 2.94 (-0.08), MDXG: 7.71 (+0.22)

Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.31 (+0.03), OHRP: 2.73 (unch)

AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 3.48 (-0.15), GILD: 80.46 (+0.99), ADHD: 4.31 (+0.03)

Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 4.13 (+0.05), ADHD: 4.31 (+0.03)

Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 4.31 (+0.03), ANAC: 99.06 (-0.14)

What's in Store for Penumbra (PEN) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:20PM CST
Penumbra, Inc. (PEN) is expected to report its fourth-quarter and full year 2015 financial numbers on Feb 11, after the market close.
VWR: 31.31 (-0.01), ADHD: 4.31 (+0.03), PEN: 68.53 (+0.22), MGLN: 65.72 (-2.75)

GNC Holdings (GNC) Q4 Earnings: A Turnaround in Store?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 11:50AM CST
The combination of GNC Holdings' (GNC) Zacks Rank #3 and +1.67% ESP makes us confident of a positive earnings beat at the company.
CNC: 69.44 (-1.11), ADHD: 4.31 (+0.03), GNC: 19.97 (-0.44), MGLN: 65.72 (-2.75)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading